Recursion Pharmaceuticals (RXRX) Operating Margin (2020 - 2025)
Historic Operating Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to 3327.57%.
- Recursion Pharmaceuticals' Operating Margin fell 29504800.0% to 3327.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 1656.17%, marking a year-over-year decrease of 10514700.0%. This contributed to the annual value of 814.09% for FY2024, which is 287600.0% down from last year.
- As of Q3 2025, Recursion Pharmaceuticals' Operating Margin stood at 3327.57%, which was down 29504800.0% from 916.75% recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' Operating Margin registered a high of 377.1% during Q3 2024, and its lowest value of 4042.41% during Q4 2024.
- Its 5-year average for Operating Margin is 1292.28%, with a median of 916.75% in 2025.
- As far as peak fluctuations go, Recursion Pharmaceuticals' Operating Margin surged by 293818100bps in 2021, and later plummeted by -31340500bps in 2024.
- Over the past 5 years, Recursion Pharmaceuticals' Operating Margin (Quarter) stood at 2564.55% in 2021, then soared by 83bps to 445.91% in 2022, then plummeted by -104bps to 908.36% in 2023, then tumbled by -345bps to 4042.41% in 2024, then increased by 18bps to 3327.57% in 2025.
- Its Operating Margin stands at 3327.57% for Q3 2025, versus 916.75% for Q2 2025 and 1297.85% for Q1 2025.